Guillermo Garcia-Manero, MD, Shares Latest Luspatercept Findings for MDS, Anemia

Dr. Garcia-Manero, of the University of Texas MD Anderson Cancer Center, discusses the latest findings on luspatercept for the treatment of patients with lower-risk myelodysplastic syndromes (MDS) and anemia.

He highlighted the final updates of the COMMANDS trial presented by Amer Zeidan, MBBS, MHS, of the Yale School of Medicine, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

“Luspatercept, when compared with an erythropoietin-stimulating agent in frontline, transfusion-dependent patients with low-risk MDS and anemia, is superior in response and duration of response compared with the standard of care,” Dr. Garcia-Manero explained.

Subsequent follow-ups on the initial analyses of the MEDALIST and COMMANDS trials will be presented at the European Hematology Association 2024 Hybrid Congress June 13-16 in Madrid, Spain. “We’re going to see new tools for the evaluation of updated response criteria,” Dr. Garcia-Manero noted.